Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort

Trédan, O; Toulmonde, M; Le Tourneau, C; Montane, L; Italiano, A; Ray-Coquard, I; de la Fouchardiere, C; Bertucci, F; Gonçalves, A; Gomez-Roca, C; You, BN; Attignon, V; Boyault, S; Cassier, PA; Dufresne, A; Tabone-Eglinger, S; Viari, A; Sohier, E; Kamal, M; Garin, G; Blay, JY; Pérol, D

Trédan, O (通讯作者)，Ctr Leon Berard, Med Oncol Dept, F-69008 Lyon, France.;Trédan, O (通讯作者)，Ctr Rech Cancerol Lyon, Inserm U1052, F-69000 Lyon, France.

CANCERS, 2023; 15 (13):

Abstract

Simple Summary Using a randomized discontinuation design, sorafenib was tested on patients with advanced/metastatic solid tumors previously treated by......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索